Status: Not yet recruiting
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56. Three dose-cohorts of VLPDEN-02 will be evaluated (1 µg, 10 µg, and 100 µg) in a dose-escalation strategy. Each dose cohort will enroll 14 participants (10 VLPDEN-02 recipients and 4 control recipients).
Participants needed: 42
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: VLP TherapeuticsUpdated: Sep 21, 2026Locations: 1
Eligibility criteria
Male or female between 18 and 55 years of age, inclusive, at the time of screeni... [+17]
Females only: Currently pregnant, as determined by positive beta-human choriogon... [+27]